1. Home
  2. NCA vs TLSI Comparison

NCA vs TLSI Comparison

Compare NCA & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California Municipal Value Fund

NCA

Nuveen California Municipal Value Fund

HOLD

Current Price

$9.41

Market Cap

307.9M

Sector

Finance

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.32

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCA
TLSI
Founded
1987
2010
Country
United States
United States
Employees
N/A
102
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
307.9M
270.2M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
NCA
TLSI
Price
$9.41
$4.32
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
58.6K
131.1K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
3.92%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$35.45
Revenue Next Year
N/A
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.33
$3.42
52 Week High
$9.80
$7.95

Technical Indicators

Market Signals
Indicator
NCA
TLSI
Relative Strength Index (RSI) 53.39 47.97
Support Level $9.17 $4.28
Resistance Level $9.55 $4.83
Average True Range (ATR) 0.15 0.23
MACD 0.01 0.01
Stochastic Oscillator 59.31 37.98

Price Performance

Historical Comparison
NCA
TLSI

About NCA Nuveen California Municipal Value Fund

Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: